Cancer Biological Therapy Market Research Report- Forecast to 2027

Cancer Biological Therapy Market Information; By Phases (Phase I, Phases II and Phases III), Type (Monoclonal Antibodies, Interferon & Interleukins, Cancer growth inhibitors, and others), End-Users (Hospitals and Clinics, Cancer Research Centers, Laboratories) - Forecast to 2027

ID: MRFR/Pharma/0123-CR | June 2017 | Region: Global | 110 pages

Impact of COVID-19 on the Cancer Biological Therapy Market


COVID-19 has become a major concern for the overall healthcare industry currently. The pandemic has directly affected the oncology-related research as well. A few Chinese studies have suggested that cancer patients are a little more vulnerable to COVID-19 than the other healthy people. According to a report published by the National Center for Biotechnology Information (NCBI) in April 2020, approximately 39% of patients suffering from cancer are at a higher risk of suffering from COVID-19, and 8% of people who do not have cancer.


Cancer biological therapy is a type of treatment that utilizes the immune system of the body to fight against cancer cells. It works in 2 ways – first, by inducing the immune system to attack the cancer cells, and second, by making cancer cells easier for the immune system to recognize. Biological therapy is widely used in lung cancer, among other types of cancer. On the other hand, COVID-19 also adversely affects the lungs. The outbreak of COVID-19 has severely affected the treatment of all the cancer patients, but most of all, the lung cancer patients, which already has a high mortality rate. According to a report published by Future Medicine Ltd, a prospective cohort study of laboratory-confirmed COVID-19 cases in China identified 18 patients with a cancer history. Lung cancer was the most common cancer type, contributing to 28% of the patients.


The pandemic is affecting the supply chain which will severely hurt global trade. China is an important destination for active pharmaceutical ingredients (API) and pharmaceutical raw material exports from several Latin American countries. China is the top trading partner of Chile, Peru, and Brazil. Additionally, the pharmaceutical sector in India is also facing hardships as India is dependent on China for procuring bulk drugs. India imports around 67% of its requirements of API from China. The manufacturers dependent on Chinese suppliers for the supply of raw materials will be devastated and production will be curtailed which will result in decreased production. These disruptions in demand and supply will eventually affect the production of immunotherapy products.


The COVID-19 outbreak has affected the supply chain of immunotherapy drugs adversely across the globe, as major companies have their manufacturing centers outside Asia. Additionally, the shortage of key raw materials and API is expected to affect the production of immunotherapy drugs. Various clinical trials related to cancer immunotherapy are also interrupted by the COVID-19 pandemic which can cause delays in the development of innovative cancer immunotherapy products.


On the other side, the number of COVID-19 patients is increasing in the Asia-Pacific region. According to the research study published in a white paper, amongst all cancer patients, approximately 4% to 5% of patients were suffering from COVID-19. The danger of COVID-19 infection is more to cancer patients due to the compromised immune system. Additionally, more than half (53.6%) cancer patients developed severe events due to corona, 21.4% were admitted to ICU, 35.7% had life-threatening complications and 28.6% of the patients died.


Thus, it is becoming difficult for doctors to suggest a universal set of recommendations for all cancer patients therefore customized treatment decisions are made for individuals. Lockdown imposed by COVID-19 can cause delay or interruption in the therapy cycle of cancer patients taking immunotherapy. Also, immunotherapy drugs are expensive as compared to other treatment options and due to the economic losses and recession, the purchasing power of patients is significantly affected. Therefore, patients are likely to opt for cheaper alternatives. This is expected to negatively affect the growth of the cancer biological therapy market.

1 Report Prologue

2 Introduction

2.1 Definition 12

2.2 Scope of Study: 12

2.3 Research Objective 12

2.4 Market Structure 13

3 Research Process

3.1.1 Primary Research: 15

3.1.2 Secondary Research: 15

4 Market Dynamics

4.1 Introduction 16

4.2 Drivers 17

4.2.1 Increasing Cancer Survival Rate 17

4.2.2 Growing Demand for Advanced Therapies 17

4.2.3 Less Number of Side Effects as Compared to Conventional Treatment Methods 17

4.2.4 Growth of Cancer Healthcare Facilities in Emerging Countries 17

4.2.5 Changing Lifestyle and Increasing Smoking Population in Middle East & Africa 18

4.3 Restraints 18

4.3.1 High cost of Cancer Biological Therapy 18

4.4 Opportunities 18

4.4.1 UnTapped Types of Cancers 18

4.5 Macroeconomic Indicators 19

5 Cancer Biological Therapy, By Phases

5.1 Introduction 20

5.2 Phases 20

6 Cancer Biological Therapy Market, By Type

6.1 Introduction 22

6.2 Monoclonal Antibodies 24

6.3 Interferons 25

6.4 Interleukins 26

6.5 Cancer growth inhibitors 26

6.6 Gene Therapy 27

6.7 Colony-Stimulating Factors 28

7 Cancer Biological Therapy Market, By End-Users

7.1 Introduction 30

7.2 Hospitals & Clinics 31

7.3 Cancer Research Centers 32

7.4 Laboratories 33

8 Global Cancer Biological Therapy, By Region

8.1 Introduction 34

8.2 North America 36

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.2.1 U.S. 40

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.2.2 Canada 42

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.3 Europe 44

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.3.1 Germany 48

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.3.2 France 50

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.3.3 U.K. 52

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.3.4 Italy 54

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.3.5 Spain 56

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.3.6 Rest Of Europe 58

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.4 Asia-Pacific 60

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.4.1 Japan 64

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.4.2 China 66

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.4.3 India 68

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.4.4 Republic of Korea 70

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.4.5 Rest of Asia-Pacific 72

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.5 Middle East & Africa 73

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.5.1 Middle East 76

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

8.5.2 Africa 81

Cancer Biological Therapy, By Phases

Cancer Biological Therapy Market, By Type

Cancer Biological Therapy Market, By End-Users

9 Competitive Landscape

9.1 Market Share Analysis 84

10 Company Profile

10.1 Amgen Inc. 85

10.1.1 Overview 85

10.1.2 Product/Business Segment Overview 85

10.1.3 Financial Overview 86

10.1.4 Key Development 87

10.2 Bristol-Myers Squibb 88

10.2.1 Overview 88

10.2.2 Product/Business Segment Overview 88

10.2.3 Financial Overview 89

10.2.4 Key Developments 90

10.3 Celgene Corporation 91

10.3.1 Overview 91

10.3.2 Product/Business Segment Overview 91

10.3.3 Financial Overview 92

10.3.4 Key Developments 93

10.4 ELI Lilly and Company 94

10.4.1 Overview 94

10.4.2 Product/Business Segment Overview 94

10.4.3 Financial Overview 95

10.4.4 Key Developments 96

10.5 EnGeneIC Ltd 97

10.5.1 Overview 97

10.5.2 Product/Business Segment Overview 97

10.5.3 Financials Updates 97

10.5.4 Key Developments 97

10.6 F. Hoffmann-La Roche AG 98

10.6.1 Overview 98

10.6.2 Product/Business Segment Overview 98

10.6.3 Financial Updates 99

10.6.4 Key Developments 100

10.7 Merck & Co., Inc. 101

10.7.1 Overview 101

10.7.2 Product/Business Segment Overview 101

10.7.3 Financial Updates 102

10.7.4 Key Developments 103

10.8 Novartis 104

10.8.1 Overview 104

10.8.2 Product/Business Segment Overview 104

10.8.3 Financial Updates 105

10.8.4 Key Developments 106

10.9 Pfizer Inc. 107

10.9.1 Overview 107

10.9.2 Product/Business Segment Overview 107

10.9.3 Financial Updates 108

10.9.4 Key Developments 109

11 List of Tables

TABLE 1 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY TYPE, 2020-2027 (USD MILLION) 23

TABLE 2 MONOCLONAL ANTIBODIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2020-2027 (USD MILLION) 24

TABLE 3 INTERFERONS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 25

TABLE 4 INTERLEUKINS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 26

TABLE 5 CANCER GROWTH INHIBITORS FOR CANCER BIOLOGIC THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 27

TABLE 6 GENE THERAPY FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 28

TABLE 7 COLONY STIMULATING FACTOR FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 29

TABLE 8 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY END USER, 2020-2027 (USD MILLION) 31

TABLE 9 HOSPITALS & CLINICS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 31

TABLE 10 CANCER RESEARCH CENTERS FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 32

TABLE 11 LABORATORIES FOR CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 33

TABLE 12 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 35

TABLE 13 NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2020-2027 (USD MILLION) 37

TABLE 14 NORTH AMERICA BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 38

TABLE 15 NORTH AMERICA BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 39

TABLE 16 U.S. CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 40

TABLE 17 U.S. CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 41

TABLE 18 CANADA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 42

TABLE 19 CANADA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 43

TABLE 20 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2020-2027 (USD MILLION) 45

TABLE 21 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 46

TABLE 22 EUROPE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 47

TABLE 23 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 48

TABLE 24 GERMANY CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 49

TABLE 25 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 50

TABLE 26 FRANCE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 51

TABLE 27 U.K. CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 52

TABLE 28 U.K. CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 53

TABLE 29 ITALY CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 54

TABLE 30 ITALY CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 55

TABLE 31 SPAIN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 56

TABLE 32 SPAIN CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 57

TABLE 33 ROE CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 58

TABLE 34 ROE CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 59

TABLE 35 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY COUNTRY 2020-2027 (USD MILLION) 61

TABLE 36 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 62

TABLE 37 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 63

TABLE 38 JAPAN CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 64

TABLE 39 JAPAN CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 65

TABLE 40 CHINA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 66

TABLE 41 CHINA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 67

TABLE 42 INDIA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 68

TABLE 43 INDIA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 69

TABLE 44 REPUBLIC OF KOREA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 70

TABLE 45 REPUBLIC OF KOREA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 71

TABLE 46 ROA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 72

TABLE 47 ROA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 73

TABLE 48 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY REGION 2020-2027 (USD MILLION) 74

TABLE 49 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 75

TABLE 50 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 76

TABLE 51 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 80

TABLE 52 MIDDLE EAST CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 81

TABLE 53 AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY TYPE 2020-2027 (USD MILLION) 82

TABLE 54 AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY END USER 2020-2027 (USD MILLION) 83

TABLE 55 AMGEN INC.: KEY DEVELOPMENT 87


12 List of Figures

FIGURE 1 RESEARCH PROCESS 14

FIGURE 2 MARKET DYNAMICS FOR GLOBAL CANCER BIOLOGICAL THERAPY MARKET 16

FIGURE 3 ATTRITION RATE OF PHASE III CLINICAL TRIALS IN EUROPE, 2020 (%) 20

FIGURE 4 CANCER BIOLOGICAL THERAPY SUCCESS RATES IN VARIOUS PHASES OF CLINICAL TRIALS 21

FIGURE 5 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY TYPE 2020 22

FIGURE 6 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY END USER, 2020 30

FIGURE 7 GLOBAL CANCER BIOLOGICAL THERAPY MARKET SHARE, BY REGION, 2020 34

FIGURE 8 NORTH AMERICA CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2020 37

FIGURE 9 EUROPE CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2020 45

FIGURE 10 ASIA PACIFIC CANCER BIOLOGICAL THERAPY MARKET SHARE, BY COUNTRY, 2020 61

FIGURE 11 MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET, BY REGION, 2020 73

FIGURE 12 QATAR: CANCER INCIDENCE AND MORTALITY RATES (%) 77

FIGURE 13 UAE: CANCER INCIDENCE AND MORTALITY RATES (%) 77

FIGURE 14 KUWAIT: CANCER INCIDENCE AND MORTALITY RATES (%) 78

FIGURE 15 BAHRAIN: CANCER INCIDENCE AND MORTALITY RATES (%) 78

FIGURE 16 OMAN: CANCER INCIDENCE AND MORTALITY RATES (%) 79

FIGURE 17 SAUDI ARABIA: CANCER INCIDENCE AND MORTALITY RATES (%) 79

FIGURE 18 GLOBAL CANCER BIOLOGICAL THERAPY MARKET: COMPANY SHARE ANALYSIS, 2020 (%) 84

FIGURE 19 AMGEN INC.: KEY FINANCIALS 86

FIGURE 20 AMGEN INC.: SEGMENTAL REVENUE 86

FIGURE 21 AMGEN INC.: GEOGRAPHICAL REVENUE 87

FIGURE 22 BRISTOL-MYERS SQUIBB.: KEY FINANCIALS 89

FIGURE 23 BRISTOL-MYERS SQUIBB.: SEGMENTAL REVENUE 89

FIGURE 24 BRISTOL-MYERS SQUIBB: GEOGRAPHICAL REVENUE 90

FIGURE 25 CELGENE CORPORATION.: KEY FINANCIALS 92

FIGURE 26 CELGENE CORPORATION.: SEGMENTAL REVENUE 92

FIGURE 27 CELGENE CORPORATION: GEOGRAPHICAL REVENUE 93

FIGURE 28 ELI LILLY AND COMPANY.: KEY FINANCIALS 95

FIGURE 29 ELI LILLY AND COMPANY.: SEGMENTAL REVENUE 95

FIGURE 30 ELI LILLY AND COMPANY: GEOGRAPHICAL REVENUE 96

FIGURE 31 F. HOFFMANN-LA ROCHE AG: FINANCIAL REVENUE 99

FIGURE 32 F. HOFFMANN-LA ROCHE AG: SEGMENTAL REVENUE 99

FIGURE 33 F. HOFFMANN-LA ROCHE AG: GEOGRPAHICAL REVENUE 100

FIGURE 34 MERCK & CO., INC: FINANCIAL REVENUE 102

FIGURE 35 MERCK & CO., INC: SEGMENTAL REVENUE 102

FIGURE 36 MERCK & CO., INC: GEOGRPAHICAL REVENUE 103

FIGURE 37 NOVARTIS: FINANCIAL REVENUE 105

FIGURE 38 NOVARTIS: SEGMENTAL REVENUE 105

FIGURE 39 NOVARTIS: GEOGRPAHICAL REVENUE 106

FIGURE 40 PFIZER INC: FINANCIAL REVENUE 108

FIGURE 41 PFIZER INC: SEGMENTAL REVENUE 108

FIGURE 42 PFIZER INC: GEOGRPAHICAL REVENUE 109